Drugs / Octagam
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03319810 | Jan → Jul 2018 | cognitive impairment with or without cerebellar ataxia | Sutter Health | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00545493 | Nov 2002 → Apr 2010 | Rasmussen subacute encephalitis | University Hospital, Bonn | Unknown | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT00811174 | Jan 2009 → Sep 2010 | immunodeficiency disease | Octapharma | Terminated | No outcome recorded |
| Phase 3 | NCT00430885 | Feb 2007 → May 2009 | acute myocardial infarction | Oslo University Hospital | Completed | Missed primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT04411667 | Apr → Jun 2020 | COVID-19 | George Sakoulas, MD | Completed | No outcome recorded |
Press releases naming this drug 5 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Octagam | “Intravenous immunoglobulins (IVIG) infusions ("Octagam"; dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of...” NCT00545493 ↗ |
| Known as | IVIg | “Octagam (IVIG)” NCT00430885 ↗ |
| Action | Restore | “Octagam 10% in replacement therapy in PID” NCT00811174 ↗ |
| Modality | Protein / enzyme biologic | “Intravenous immunoglobulin 0.4 g/kg given as infusion” NCT00430885 ↗ |
| Route | Intravenous | “Intravenous immunoglobulin 0.4 g/kg given as infusion” NCT00430885 ↗ |